Brought to you by 
Denali could pay big in new F-star deal; holds option to acquire
20 Sep 2017
Executive Summary
Denali Therapeutics Inc. and F-star GMBH, through its newly created asset-centric vehicle F-star Gamma Ltd., entered into a collaboration to discover and develop new neurological disease therapies that can be delivered into the CNS across the blood-brain barrier. Denali also gained an option to acquire F-star Gamma prior to Phase I trials.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes M&A Option
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com